Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...

Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an ...

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...